Showing results (431-440 of 511) with videos related to
Sort By:
Pageof 52
Nature Medicine|April 8, 2014
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageAaron M Newman, Scott V Bratman, Jacqueline To, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.British Journal of Cancer|July 19, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumoursI Diaz-Padilla, L L Siu, M San Pedro-Salcedo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 21, 2023
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic AgentsBrianna C Lau, Yufan F Wu, Hyunsoo J No, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.JAMA Network Open|November 15, 2023
Second Primary Lung Cancer Among Lung Cancer Survivors Who Never SmokedEunji Choi, Chloe C Su, Julie T Wu, et al.JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.Clinical Lung Cancer|September 23, 2023
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart ReviewJürgen Wolf, Pierre-Jean Souquet, Koichi Goto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.Pageof 52